Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

135.91 +0.69 (+0.51%)
Official Closing Price Updated: 4:10 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 719,304
Open 135.43
Bid (Size) 133.07 (1)
Ask (Size) 138.57 (1)
Prev. Close 135.22
Today's Range 135.19 - 136.24
52wk Range 119.59 - 158.34
Shares Outstanding 122,180,759
Dividend Yield 2.09%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings for Quest Diagnostics
Via Benzinga
Opioid Crisis and Corporate Accountability: Purdue's Settlement in the Spotlight
The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family.  
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal

Performance

YTD
-12.75%
-12.75%
1 Month
+2.28%
+2.28%
3 Month
+6.92%
+6.92%
6 Month
+0.18%
+0.18%
1 Year
-8.79%
-8.79%

More News

Read More
Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Quest Diagnostics
Via Benzinga
Firing on All Cylinders Indeed
Via The Motley Fool
Making Connections To Care: Quest Supports Inspiring Health Equity Event Hosted by Sisters on the Vineyard
Via ACCESSWIRE
Quest Diagnostics: Dividend Insights
Via Benzinga
Quest Diagnostics Q3: 7.7% Topline Decline, Earnings Beat, Updated Guidance & More
Via Benzinga
Topics Earnings
Exposures Financial
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Via FinancialNewsMedia
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Via Benzinga
Analyst Ratings for Quest Diagnostics
Via Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
Via Benzinga
Exposures COVID-19
3 Pharma Stocks to Buy as Summer COVID Cases Spike
Via InvestorPlace
Exposures COVID-19
Why Bionano Genomics Stock Tanked Today
Via The Motley Fool
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Via The Motley Fool
Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023
Via InvestorPlace
Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook
Via Benzinga
Sustaining Growth Momentum: Quest Diagnostics Continues to Excel and Reports Rising Profits
Via Benzinga
Quest Diagnostics, Keysight Technologies And A Stock Up 42% Year To Date On CNBC's 'Final Trades'
Via Benzinga
Biden Administration Releases Revised Guidance For Medicare Drug Price Negotiation Amid Industry Lawsuits
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
FDA Readies Proposal for Increased Oversight on Lab-developed Tests
Via Benzinga
Want Growing Passive Income? Consider Buying This Stock
Via The Motley Fool
Post-Accident Workforce Drug Positivity For Marijuana Reached 25-Year High In 2022, Quest Diagnostics Drug Testing Index Analysis Finds
Via Benzinga
Exact Sciences Serves Investors Exactly What They Wished For
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.